Liver disease symptoms are associated with higher risk of adverse clinical outcomes: A longitudinal study of North American adults with chronic Hepatitis B

GastroHep Pub Date : 2021-05-05 DOI:10.1002/ygh2.458
Donna M. Evon, Hsing-Hua S. Lin, Robert J. Fontana, Mandana Khalili, Colina Yim, Abdus S. Wahed, Jay H. Hoofnagle, the Hepatitis B Research Network (HBRN)
{"title":"Liver disease symptoms are associated with higher risk of adverse clinical outcomes: A longitudinal study of North American adults with chronic Hepatitis B","authors":"Donna M. Evon,&nbsp;Hsing-Hua S. Lin,&nbsp;Robert J. Fontana,&nbsp;Mandana Khalili,&nbsp;Colina Yim,&nbsp;Abdus S. Wahed,&nbsp;Jay H. Hoofnagle,&nbsp;the Hepatitis B Research Network (HBRN)","doi":"10.1002/ygh2.458","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Symptoms of chronic hepatitis B (CHB) are not well characterised.</p>\n </section>\n \n <section>\n \n <h3> Aims</h3>\n \n <p>To evaluate CHB symptoms and associations with disease activity and clinical outcomes.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Longitudinal data from 1576 participants in the Hepatitis B Research Network Cohort Study who completed symptom assessments were analysed. A composite symptom score was calculated using a Symptom Checklist (0 = none to 40 = extreme). Multivariable mixed models assessed variables associated with symptom change over time. Latent class symptom trajectories were evaluated. The cumulative probability of long-term clinical outcomes (new onset cirrhosis, hepatic decompensation, hepatocellular carcinoma, liver transplantation, death) was examined by baseline symptom groups.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Participants median age was 42 (range: 18-80), 51% were male, 75% Asian, (68% of whom were born outside North America) with a median follow-up of 4.2 years. On average, symptoms did not significantly change over time. The multivariable model identified several variables associated with higher symptoms during follow-up: being female, non-Asian, born in the United States/Canada, lower education, higher AST, lower platelets and more comorbidities. Two patient subgroups were identified based on longitudinal symptom trajectories: a low symptom group (92%, n = 1451) with symptom scores averaging 2.4 over time and a moderate symptom group (8%, n = 125) with symptom scores averaging 11.5. During follow-up, 7.3% in the moderate symptom group, but only 3.2% of the low symptom group, developed adverse outcomes (<i>P</i> = 0.02).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>In this large cohort of CHB patients, symptoms were generally mild and stable over time. However, in some patients with moderate symptoms at baseline, deleterious clinical outcomes were more frequent at follow-up.</p>\n \n <p>ClinicalTrials.gov Identifier: NCT01263587.</p>\n </section>\n </div>","PeriodicalId":12480,"journal":{"name":"GastroHep","volume":"3 3","pages":"196-208"},"PeriodicalIF":0.0000,"publicationDate":"2021-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/ygh2.458","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"GastroHep","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ygh2.458","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Background

Symptoms of chronic hepatitis B (CHB) are not well characterised.

Aims

To evaluate CHB symptoms and associations with disease activity and clinical outcomes.

Methods

Longitudinal data from 1576 participants in the Hepatitis B Research Network Cohort Study who completed symptom assessments were analysed. A composite symptom score was calculated using a Symptom Checklist (0 = none to 40 = extreme). Multivariable mixed models assessed variables associated with symptom change over time. Latent class symptom trajectories were evaluated. The cumulative probability of long-term clinical outcomes (new onset cirrhosis, hepatic decompensation, hepatocellular carcinoma, liver transplantation, death) was examined by baseline symptom groups.

Results

Participants median age was 42 (range: 18-80), 51% were male, 75% Asian, (68% of whom were born outside North America) with a median follow-up of 4.2 years. On average, symptoms did not significantly change over time. The multivariable model identified several variables associated with higher symptoms during follow-up: being female, non-Asian, born in the United States/Canada, lower education, higher AST, lower platelets and more comorbidities. Two patient subgroups were identified based on longitudinal symptom trajectories: a low symptom group (92%, n = 1451) with symptom scores averaging 2.4 over time and a moderate symptom group (8%, n = 125) with symptom scores averaging 11.5. During follow-up, 7.3% in the moderate symptom group, but only 3.2% of the low symptom group, developed adverse outcomes (P = 0.02).

Conclusions

In this large cohort of CHB patients, symptoms were generally mild and stable over time. However, in some patients with moderate symptoms at baseline, deleterious clinical outcomes were more frequent at follow-up.

ClinicalTrials.gov Identifier: NCT01263587.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
肝病症状与较高的不良临床结果风险相关:一项对北美成年慢性乙型肝炎患者的纵向研究
背景:慢性乙型肝炎(CHB)的症状没有很好的特征。目的评价慢性乙型肝炎的症状及其与疾病活动性和临床结果的关系。方法对1576名完成症状评估的乙型肝炎研究网络队列研究参与者的纵向资料进行分析。使用症状检查表计算综合症状评分(0 =无至40 =极端)。多变量混合模型评估与症状随时间变化相关的变量。评估潜在类别症状轨迹。通过基线症状组检测长期临床结局(新发肝硬化、肝功能失代偿、肝细胞癌、肝移植、死亡)的累积概率。参与者的中位年龄为42岁(范围:18-80岁),51%为男性,75%为亚洲人(其中68%出生在北美以外),中位随访时间为4.2年。平均而言,随着时间的推移,症状没有显著变化。在随访期间,多变量模型确定了与较高症状相关的几个变量:女性、非亚洲人、出生在美国/加拿大、受教育程度较低、AST较高、血小板较低和更多合并症。根据纵向症状轨迹确定了两个患者亚组:低症状组(92%,n = 1451),症状评分随时间推移平均为2.4分;中度症状组(8%,n = 125),症状评分平均为11.5分。随访期间,中度症状组出现不良结局的比例为7.3%,而轻度症状组出现不良结局的比例仅为3.2% (P = 0.02)。结论:在这一大批慢性乙型肝炎患者中,随着时间的推移,症状通常是轻微和稳定的。然而,在一些基线时症状中等的患者中,在随访中更常见有害的临床结果。ClinicalTrials.gov标识符:NCT01263587。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Hepatitis D Virus Status Among People With Hepatitis B Virus Infection: A Disconnect Between Guidelines and Practice The Use of Antibiotics for the Prophylaxis of Spontaneous Bacterial Peritonitis: A Retrospective Review and Quality Improvement Study Management of Antithrombotic Agents During Emergency Endoscopy for Upper Gastrointestinal Bleeding: A Propensity Score Matching Analysis High Technical Success Rate of Endoscopic Balloon Dilatation Reduces Surgical Requirement for Patients With Stricturing Crohn’s Disease The Suitability of Stool Antigen Testing in the Detection of Helicobacter pylori in a Regional and Rural Area of Australia
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1